Developer docs
API playgroundTry for free, no card

Search company profiles

92Bio

Full company profile

uuid002176a

Namestring
92Bio
Legal namestring
92Bio, Inc.
Websiteurl
92biotech.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

92Bio, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2023 and headquartered in Hayward, California, that develops multi-specific T-cell engager (TCE) biologic therapies for cancer. The company's pipeline is built around two lead programs: NTB-928, a potentially best-in-class folate receptor alpha (FRα) x CD3 TCE for FRα-expressing solid tumors (and selected hematologic tumors) on track to enter the clinic in the first half of 2026, and a first-in-class CD123 x gamma delta (γδ) T-cell engager for acute myeloid leukemia (AML) slated for clinical entry in 2027, with additional undisclosed solid and hematologic tumor programs referenced as future work.

The underlying technology is a proprietary multi-specific antibody design platform that combines conventional CD3-engaging TCE biology with a novel γδ T-cell engaging modality, leveraging the γδ T-cell subset's association with favorable cancer outcomes to create fit-for-purpose therapeutics. 92Bio's revenue model is licensing/royalties tied to future commercialization; the company is pre-revenue with no marketed products, and distribution is expected to flow through standard pharmaceutical channels (specialty pharmacies, hospital systems, oncology centers) post-approval. Customers/end-beneficiaries are defined by indication: hematologic cancer patients (notably AML) and solid tumor patients with FRα expression, and go-to-market activity is concentrated on scientific publication and conference engagement rather than commercial sales.

The company is venture-backed by a syndicate of Lightspeed, Firebrand River Capital, Bluebird Ventures, and SR One, each with board representation, and is led by CEO Ben Buelow, MD, PhD (former CMO of Teneobio, acquired by Amgen for up to $2.5B), supported by a CDO and four PhD-level VPs across Discovery Biology, Biologics, Informatics, and Clinical Operations. Marketing efforts to date are limited to a LinkedIn presence, an SITC 2025 poster on the CD123 x γδ TCE, and the company website; no patents, awards, certifications, M&A, or material leadership departures are disclosed.

Short descriptiontext

92Bio is a pre-revenue, clinical-stage biotech founded in 2023 that develops multi-specific T-cell engager (TCE) biologics for cancer, advancing NTB-928 (FRα x CD3 TCE) into the clinic in H1 2026 and a γδ TCE for AML in 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHayward, United States
HQ citystring
Hayward
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
T-cell engagers, multi-specific antibodies, cancer immunotherapy, bispecific biologics, gamma delta T-cells
Industry2 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biologics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeLicensing Royalties
Description

Pre-revenue clinical stage biopharmaceutical company. Revenue will be generated through commercialization of novel antibody therapeutics upon successful clinical development and regulatory approval. Pipeline includes NTB-928 for solid tumors and γδ T-cell engaging drugs for hematologic malignancies.

92biotech.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

92Bio is a clinical-stage biopharmaceutical company developing novel, best-in-class multi-specific T-cell engager (TCE) antibody therapeutics for cancer. Its two lead candidates are NTB-928, an FRα x CD3 TCE for solid tumors entering the clinic in H1 2026, and a CD123 x gamma delta (γδ) T-cell engager for acute myeloid leukemia expected to enter the clinic in 2027. The company leverages multi-specific antibody design and novel γδ T-cell immune subsets to create fit-for-purpose cancer therapeutics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • NTB-928 on track to enter clinic in H1 2026; γδ T-cell engaging drug for AML slated for clinical entry in 2027
Product overview1 text field

92Bio is a clinical-stage biotech company developing novel, best-in-class multispecific biologics (T-cell engagers/TCEs) for cancer treatment. The company's pipeline includes two lead programs: NTB-928, a FRα x CD3 TCE targeting solid and hematologic tumors entering Phase 1 in first half 2026; and a CD123 x gamma delta T cell engager for acute myeloid leukemia expected to enter the clinic in 2027. 92Bio leverages advances in multi-specific antibody design and novel immune cell subsets (particularly gamma delta T-cells) to create fit-for-purpose TCEs.

Product and service2 records
1NTB-928
CategoryOncology Biologic / T-cell Engager
Description

Potentially best-in-class folate receptor alpha (FRα) x CD3 T-cell engager (TCE) candidate for the treatment of FRα-expressing solid tumors; designed to bind tumor antigens and T-cell receptors simultaneously to redirect T-cell cytotoxicity to cancer cells.

2CD123 x gamma delta T cell engager
CategoryOncology Biologic / γδ T-cell Engager
Description

First-in-class novel γδ T-cell engaging drug candidate targeting CD123 for the treatment of acute myeloid leukemia (AML), leveraging the γδ T-cell immune subset strongly linked to favorable cancer outcomes.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing multi-specific antibodies including TCEs for oncology indications. Closely comparable in stage, modality, and clinical execution profile.

TypeBroad incumbent
Description

Acquirer of Teneobio (92Bio CEO's prior company) and developer/marketer of Blincyto (CD19 x CD3 TCE). Sets the competitive standard in TCEs and represents a potential strategic acquirer for 92Bio.

TypeEmerging player
Description

Develops engineered T-cell therapies (SPEAR T-cells) including TCR-T approaches for solid tumors. Mechanistically adjacent — both approaches leverage engineered T-cell receptor biology for cancer targeting.

TypeDirect peer
Description

Developed a T-cell engager platform (HPN424, HPN536) for solid tumors before being acquired by Merck. Closest direct analog as a clinical-stage multi-specific TCE developer with similar target profiles.

TypeBroad incumbent
Description

Established clinical-stage biotech with a portfolio of multi-specific DART and TRIDENT TCE molecules targeting both solid and hematologic tumors. Larger and more mature peer with multiple clinical-stage TCE programs.

TypeEmerging player
Description

Develops masked, conditionally activated antibody therapeutics (Probodies) including TCEs for solid tumors. Comparable in being a clinical-stage platform company targeting solid tumor TCEs with novel engineering.

TypeBroad incumbent
Description

Developer of the DuoBody bispecific antibody platform, with multiple approved and clinical-stage TCEs (e.g., epcoritamab). Established platform peer in multi-specific antibody engineering for oncology.

TypeDirect peer
Description

Developed a T-cell engager platform (COBRA) targeting solid tumors; acquired by Takeda in 2021. Direct precedent for a TCE platform company reaching an exit via strategic acquisition.

TypeDirect peer
Description

Clinical-stage oncology company developing multi-specific immunotherapies including TCEs. Comparable stage, modality, and indication focus (including hematologic malignancies).

TypeEmerging player
Description

Clinical-stage biotech using AI-driven antibody discovery to develop multi-specific antibodies for oncology. Comparable stage and platform-driven multi-specific antibody approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

92Bio

Oncology Biologics92biotech.com

92Bio is a pre-revenue, clinical-stage biotech founded in 2023 that develops multi-specific T-cell engager (TCE) biologics for cancer, advancing NTB-928 (FRα x CD3 TCE) into the clinic in H1 2026 and a γδ TCE for AML in 2027.

What 92Bio does

92Bio, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2023 and headquartered in Hayward, California, that develops multi-specific T-cell engager (TCE) biologic therapies for cancer. The company's pipeline is built around two lead programs: NTB-928, a potentially best-in-class folate receptor alpha (FRα) x CD3 TCE for FRα-expressing solid tumors (and selected hematologic tumors) on track to enter the clinic in the first half of 2026, and a first-in-class CD123 x gamma delta (γδ) T-cell engager for acute myeloid leukemia (AML) slated for clinical entry in 2027, with additional undisclosed solid and hematologic tumor programs referenced as future work.

The underlying technology is a proprietary multi-specific antibody design platform that combines conventional CD3-engaging TCE biology with a novel γδ T-cell engaging modality, leveraging the γδ T-cell subset's association with favorable cancer outcomes to create fit-for-purpose therapeutics. 92Bio's revenue model is licensing/royalties tied to future commercialization; the company is pre-revenue with no marketed products, and distribution is expected to flow through standard pharmaceutical channels (specialty pharmacies, hospital systems, oncology centers) post-approval. Customers/end-beneficiaries are defined by indication: hematologic cancer patients (notably AML) and solid tumor patients with FRα expression, and go-to-market activity is concentrated on scientific publication and conference engagement rather than commercial sales.

The company is venture-backed by a syndicate of Lightspeed, Firebrand River Capital, Bluebird Ventures, and SR One, each with board representation, and is led by CEO Ben Buelow, MD, PhD (former CMO of Teneobio, acquired by Amgen for up to $2.5B), supported by a CDO and four PhD-level VPs across Discovery Biology, Biologics, Informatics, and Clinical Operations. Marketing efforts to date are limited to a LinkedIn presence, an SITC 2025 poster on the CD123 x γδ TCE, and the company website; no patents, awards, certifications, M&A, or material leadership departures are disclosed.

92Bio firmographics

Firmographics
Name
92Bio
Legal name
92Bio, Inc.
Website
https://92biotech.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
92Bio is a pre-revenue, clinical-stage biotech founded in 2023 that develops multi-specific T-cell engager (TCE) biologics for cancer, advancing NTB-928 (FRα x CD3 TCE) into the clinic in H1 2026 and a γδ TCE for AML in 2027.
Ownership category
akta.pro rank

92Bio industry classification

Industry
Product category
Oncology Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • T-cell engagers
  • Multi-specific antibodies
  • Cancer immunotherapy
  • Bispecific biologics
  • Gamma delta T-cells

Where 92Bio is headquartered

Location

Headquarters

HQ city
Hayward
HQ country
United States
HQ region
North America

Offices1 record

Markets served

92Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development and Commercialization: Pre-revenue clinical stage biopharmaceutical company. Revenue will be generated through commercialization of novel antibody therapeutics upon successful clinical development and regulatory approval. Pipeline includes NTB-928 for solid tumors and γδ T-cell engaging drugs for hematologic malignancies.

Go-to-market motion1 record

Marketing channels3 records

92Bio product offering

Product offering

Core offering

92Bio is a clinical-stage biopharmaceutical company developing novel, best-in-class multi-specific T-cell engager (TCE) antibody therapeutics for cancer. Its two lead candidates are NTB-928, an FRα x CD3 TCE for solid tumors entering the clinic in H1 2026, and a CD123 x gamma delta (γδ) T-cell engager for acute myeloid leukemia expected to enter the clinic in 2027. The company leverages multi-specific antibody design and novel γδ T-cell immune subsets to create fit-for-purpose cancer therapeutics.

Product overview

92Bio is a clinical-stage biotech company developing novel, best-in-class multispecific biologics (T-cell engagers/TCEs) for cancer treatment. The company's pipeline includes two lead programs: NTB-928, a FRα x CD3 TCE targeting solid and hematologic tumors entering Phase 1 in first half 2026; and a CD123 x gamma delta T cell engager for acute myeloid leukemia expected to enter the clinic in 2027. 92Bio leverages advances in multi-specific antibody design and novel immune cell subsets (particularly gamma delta T-cells) to create fit-for-purpose TCEs.

Differentiator

Problem solved

Functional benefit

Products and services

  • NTB-928 Potentially best-in-class folate receptor alpha (FRα) x CD3 T-cell engager (TCE) candidate for the treatment of FRα-expressing solid tumors; designed to bind tumor antigens and T-cell receptors simultaneously to redirect T-cell cytotoxicity to cancer cells.
  • CD123 x gamma delta T cell engager First-in-class novel γδ T-cell engaging drug candidate targeting CD123 for the treatment of acute myeloid leukemia (AML), leveraging the γδ T-cell immune subset strongly linked to favorable cancer outcomes.

Quantifiable outcome

  • NTB-928 on track to enter clinic in H1 2026; γδ T-cell engaging drug for AML slated for clinical entry in 2027

Companies that use 92Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

92Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

92Bio partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

92Bio competitors and assessment

Company assessment

Direct peers

  • Compass Therapeutics: Clinical-stage biotech developing multi-specific antibodies including TCEs for oncology indications. Closely comparable in stage, modality, and clinical execution profile.
  • Harpoon Therapeutics: Developed a T-cell engager platform (HPN424, HPN536) for solid tumors before being acquired by Merck. Closest direct analog as a clinical-stage multi-specific TCE developer with similar target profiles.
  • Maverick Therapeutics (Takeda): Developed a T-cell engager platform (COBRA) targeting solid tumors; acquired by Takeda in 2021. Direct precedent for a TCE platform company reaching an exit via strategic acquisition.
  • Cullinan Oncology: Clinical-stage oncology company developing multi-specific immunotherapies including TCEs. Comparable stage, modality, and indication focus (including hematologic malignancies).

Broad incumbents

  • Amgen: Acquirer of Teneobio (92Bio CEO's prior company) and developer/marketer of Blincyto (CD19 x CD3 TCE). Sets the competitive standard in TCEs and represents a potential strategic acquirer for 92Bio.
  • MacroGenics: Established clinical-stage biotech with a portfolio of multi-specific DART and TRIDENT TCE molecules targeting both solid and hematologic tumors. Larger and more mature peer with multiple clinical-stage TCE programs.
  • Genmab: Developer of the DuoBody bispecific antibody platform, with multiple approved and clinical-stage TCEs (e.g., epcoritamab). Established platform peer in multi-specific antibody engineering for oncology.

Emerging players

  • Adaptimmune Therapeutics: Develops engineered T-cell therapies (SPEAR T-cells) including TCR-T approaches for solid tumors. Mechanistically adjacent — both approaches leverage engineered T-cell receptor biology for cancer targeting.
  • CytomX Therapeutics: Develops masked, conditionally activated antibody therapeutics (Probodies) including TCEs for solid tumors. Comparable in being a clinical-stage platform company targeting solid tumor TCEs with novel engineering.
  • Adagene: Clinical-stage biotech using AI-driven antibody discovery to develop multi-specific antibodies for oncology. Comparable stage and platform-driven multi-specific antibody approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

92Bio social profiles

Digital presence

92Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

92Bio leadership team

Management profile

Number of profiles

Profiles10 records

92Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

92Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 92Bio

What does 92Bio do?

92Bio is a clinical-stage biopharmaceutical company developing novel, best-in-class multi-specific T-cell engager (TCE) antibody therapeutics for cancer. Its two lead candidates are NTB-928, an FRα x CD3 TCE for solid tumors entering the clinic in H1 2026, and a CD123 x gamma delta (γδ) T-cell engager for acute myeloid leukemia expected to enter the clinic in 2027. The company leverages multi-specific antibody design and novel γδ T-cell immune subsets to create fit-for-purpose cancer therapeutics.

Is 92Bio a public or private company?

92Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was 92Bio founded?

92Bio was founded in 2023. It employs 11 to 50 people.

Where is 92Bio based?

92Bio is headquartered in Hayward, United States, in the North America region.

How does 92Bio make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are 92Bio's main competitors?

Direct peers on record are Compass Therapeutics, Harpoon Therapeutics, Maverick Therapeutics (Takeda) and Cullinan Oncology. Broad incumbents are Amgen, MacroGenics and Genmab. Emerging players are Adaptimmune Therapeutics, CytomX Therapeutics and Adagene.

Does 92Bio have an API?

No public API is recorded for 92Bio.

What industry is 92Bio in?

92Bio's product category is Oncology Biologics. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvest92Bio Doses First Patient in NTB-928 Ovarian Cancer Trial - But the Funding Gap Is the Real Risk92Bio has dosed the first patient in a Phase 1 clinical trial for NTB-928, a T-cell engager targeting ovarian cancer, despite being described as an unfunded startup founded in 2023. The asset originated from Amgen's $900M acquisition of Teneobio in 2021 and was subsequently deprioritized before being revived by 92Bio, raising questions about why a major pharmaceutical company passed on the program. With Phase 1-2 oncology trials typically costing tens to hundreds of millions of dollars and no disclosed capital raises or partnerships to date, the company faces significant funding challenges to advance the program beyond this early milestone.Business Wire Blog92Bio, Inc. Doses First Patient in Phase 1 Clinical Trial of NTB-928 in Platinum-Resistant Ovarian Cancer92Bio, Inc. announced the dosing of the first patient in a Phase 1 clinical trial evaluating NTB-928 for platinum-resistant ovarian cancer, with the initial dose administered at START New York-Long Island. NTB-928 is a bispecific T-cell engaging antibody engineered to selectively target FOLR1-overexpressing tumor cells while sparing normal tissues that express trace FOLR1—a key limitation of conventional approaches targeting this antigen, which is overexpressed in over 75% of ovarian cancers. The trial uses a Bayesian Optimal Interval dose-escalation design to evaluate safety, tolerability, and preliminary activity of the compound.FinancialContent Business Page92Bio, Inc. Doses First Patient in Phase 1 Clinical Trial of NTB-928 in Platinum-Resistant Ovarian Cancer92Bio, Inc. has dosed the first patient in a Phase 1 clinical trial evaluating NTB-928 for platinum-resistant ovarian cancer, conducted at multiple US trial sites with the initial patient treated at START New York-Long Island. NTB-928 is a bispecific T-cell engaging antibody engineered to selectively target FOLR1-overexpressing tumor cells while sparing normal tissues that express trace FOLR1—a key limitation of conventional FOLR1-targeted approaches. FOLR1 is overexpressed in more than 75% of ovarian cancer cases, and the trial uses a Bayesian Optimal Interval dose-escalation design to evaluate safety, tolerability, and preliminary activity.Morningstar92Bio, Inc. Doses First Patient in Phase 1 Clinical Trial of NTB-928 in Platinum-Resistant Ovarian Cancer92Bio, Inc. dosed the first patient in a Phase 1 trial of NTB-928 for platinum-resistant ovarian cancer, with the first dose at START New York-Long Island. The bispecific T-cell engager targets FOLR1 and CD3, designed to spare normal tissues. The trial uses a Bayesian dose-escalation design to evaluate safety and preliminary activity.CRISPR MedicinePress Release Service: Leveragen and 92Bio Forge Strategic Alliance to Advance Therapeutics Using Novel Single Domain Antibody PlatformLeveragen, Inc. and 92Bio have entered into a multi-target commercial license agreement to advance therapeutics using Leveragen's Singularity Sapiens Mouse platform for single-domain antibody discovery. Under the terms of this strategic alliance, 92Bio will receive exclusive rights to develop and market antibodies produced via this technology, while Leveragen will secure upfront payments, milestone payments, and royalties. The collaboration aims to leverage Leveragen's genetic engineering capabilities combined with 92Bio's expertise in developing therapeutic antibodies.